Cascone, Tina http://orcid.org/0000-0003-3008-5407
Weissferdt, Annikka
Godoy, Myrna C. B.
William, William N. Jr.
Leung, Cheuk H.
Lin, Heather Y.
Basu, Sreyashi http://orcid.org/0000-0002-5028-3833
Yadav, Shalini S.
Pataer, Apar
Mitchell, Kyle G.
Khan, Md Abdul Wadud http://orcid.org/0000-0003-0596-862X
Shi, Yushu
Haymaker, Cara http://orcid.org/0000-0002-1317-9287
Solis, Luisa M. http://orcid.org/0000-0002-1253-630X
Parra, Edwin R. http://orcid.org/0000-0001-9068-1636
Kadara, Humam
Wistuba, Ignacio I.
Sharma, Padmanee
Allison, James P.
Ajami, Nadim J. http://orcid.org/0000-0002-3808-8576
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
Jenq, Robert R.
Gibbons, Don L. http://orcid.org/0000-0003-2362-3094
Lee, J. Jack http://orcid.org/0000-0001-5469-9214
Swisher, Stephen G. http://orcid.org/0000-0002-3080-1920
Vaporciyan, Ara A.
Heymach, John V. http://orcid.org/0000-0001-9068-8942
Sepesi, Boris
Article History
Received: 21 February 2020
Accepted: 27 July 2021
First Online: 19 August 2021
Competing interests
: T. Cascone has received speaker’s fees from the Society for Immunotherapy of Cancer, Bristol Myers Squibb and Roche; reports consultant/advisory role fees from MedImmune/AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech and Arrowhead Pharmaceuticals; and reports clinical research funding to The University of Texas MD Anderson Cancer Center from Boehringer Ingelheim, MedImmune/AstraZeneca, Bristol Myers Squibb, and EMD Serono. M.C.B. Godoy has received research funding from Siemens Healthcare. W.N. William Jr. has received honoraria/speaker’s fees and/or participated in advisory boards from Roche/Genentech, Bristol Myers Squibb, Eli Lilly, Merck, AstraZeneca, and Pfizer. C. Haymaker reports personal fees from Nanobiotix and science advisory board fees from Briacell. H. Kadara has received funding from Johnson and Johnson. I.I. Wistuba has provided consulting or advisory roles for AstraZeneca/MedImmune, Asuragen, Bayer, Bristol Myers Squibb, Genentech/Roche, GlaxoSmithKline, Guardant Health, HTG Molecular Diagnostics, Merck, MSD Oncology, OncoCyte, Novartis, Flame Inc., and Pfizer; has received grants and personal fees from Asuragen, Genentech/Roche, Bristol Myers Squibb, AstraZeneca/MedImmune, HTG Molecular, Merck, and Guardant Health; has received personal fees from GlaxoSmithKline, OncoCyte, Daiichi-Sankyo, Roche, AstraZeneca, Pfizer, and Bayer; has received research funding to his institution from 4D Molecular Therapeutics, Adaptimmune, Adaptive Biotechnologies, Akoya Biosciences, Amgen, Bayer, EMD Serono, Genentech, Guardant Health, HTG Molecular Diagnostics, Iovance Biotherapeutics, Johnson & Johnson, Karus Therapeutics, MedImmune, Merck, Novartis, OncoPlex Diagnostics, Pfizer, Silicon Biosystems, Takeda, and Novartis. P. Sharma reports consulting, advisory roles, and/or stocks/ownership for Achelois, Apricity Health, BioAlta, Codiak BioSciences, Constellation, Dragonfly Therapeutics, Forty-Seven Inc., Hummingbird, ImaginAb, Jounce Therapeutics, Lava Therapeutics, Lytix Biopharma, Marker Therapeutics, Oncolytics, Infinity Pharma, BioNTech, Adaptive Biotechnologies, and Polaris; and owns a patent licensed to Jounce Therapeutics (61/247,438; “Combination Immunotherapy for the Treatment of Cancer”). J.P. Allison reports consulting, advisory roles, and/or stocks/ownership for Achelois, Apricity Health, BioAtla, Codiak BioSciences, Dragonfly Therapeutics, Forty-Seven Inc., Hummingbird, ImaginAb, Jounce Therapeutics, Lava Therapeutics, Lytix Biopharma, Marker Therapeutics, Polaris, BioNTech, and Adaptive Biotechnologies; and owns a patent licensed to Jounce Therapeutics (61/247,438; “Combination Immunotherapy for the Treatment of Cancer”). J.A. Wargo is an inventor on a US patent application PCT/US17/53,717, “Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome”, submitted by the University of Texas MD Anderson Cancer Center and on a patent “Targeting B Cells To Enhance Response To Immune Checkpoint Blockade” UTSC.P1412US.P1 - MDA19-023. J.A. Wargo reports honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol-Myers Squibb. J. Wargo serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Diversigen, Micronoma, and Ella Therapeutics. R.R. Jenq receives consultant role fees from Merck, Karius and Microbiome DX, advisory member role fees from Seres and Kaleido and patent licensing fees from Seres (US20170258854A1; “Intestinal microbiota and gvhd”). D.L. Gibbons has served on scientific advisory committees for AstraZeneca, GlaxoSmithKline, Sanofi, Eli Lilly, and Janssen; has received research support from Janssen, Takeda, Ribon Therapeutics, Astellas, and AstraZeneca. S.G. Swisher has participated in advisory committees for Ethicon and for the Peter MacCallum Cancer Center. J.V. Heymach has received research support from AstraZeneca, GlaxoSmithKline, and Spectrum; participated in advisory committees for AstraZeneca, Boehringer Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Specrtum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, Bristol Myers Squibb, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health System, Pneuma Respiratory, Kairos Venture Investments, Roche, and Leads Biolabs; and received royalties and/or licensing fees from Spectrum. B. Sepesi receives consultant/advisory role fees from Bristol Myers Squibb. No potential conflicts of interest are disclosed by the other authors.